FDA wants investigation into Avandia conflict: report

NEW YORK Sat Jul 24, 2010 4:11am IST

Related Topics

Stocks

   

NEW YORK (Reuters) - The U.S. Food and Drug Administration has asked the Department of Health and Human Services to investigate whether one of the panelists at a recent safety meeting on the GlaxoSmithKline PLC drug Avandia had a conflict of interest, according to a report by the Wall Street Journal.

David Capuzzi, an endocrinologist in Philadelphia, has received $14,000 from Glaxo for speaking on behalf of another drug, Lovaza, according to the newspaper report.

Capuzzi said he told the FDA about his connection to Glaxo and the FDA said it had vetted all members of its advisory panel for conflicts, the newspaper reported.

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Ebola Outbreak

Eat That Carrot

Eat That Carrot

Start early for a lifetime of good vision and healthy eyes.  Full Article 

Triggering Violence

Triggering Violence

What makes hospital patients turn violent?  Full Article 

Corruption Issue

Corruption Issue

After China, GlaxoSmithKline faces pressure for change.  Full Article 

Good Or Bad?

Good Or Bad?

Study of smoking cancer patients fuels e-cigarette debate.  Full Article 

Much-Needed

Much-Needed

Allowing blood donations from gay men could help save over a million lives: U.S. study.  Full Article 

Not Aware

Not Aware

Kidney patients know little about transplant benefits.  Full Article 

Get Up

Get Up

Sedentary lifestyle linked to depression.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage